Abstract
The demand of fertility preservation with no urgent medical indication or for social reasons has increased in recent years.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Birch Petersen K, et al. Family intentions and personal considerations on postponing childbearing in childless cohabiting and single women aged 35–43 seeking fertility assessment and counseling. Hum Reprod. 2015;30(11):2563–74.
Cobo A, et al. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril. 2016;105(3):755–64. e8
Cobo A, García-Velasco JA. Why all women should freeze their egg. Curr Opin Obstet Gynecol. 2016;28(3):206–10.
Menken J, Trussell J, Larsen U. Age and infertility. Science. 1986;234(5775):413.
FJM B, et al. Back to the basics of ovarian aging: a population-based study on longitudinal anti-Müllerian hormone decline. BMC Med. 2016;14(1):151.
Armstrong D. Effects of maternal age on oocyte developmental competence. Theriogenology. 2001;55(6):1303–22.
Allersma T, Farquhar C, Cantineau AE. Natural cycle in vitro fertilisation (IVF) for subfertile couples. Cochrane Database Syst Rev. 2013;30(8):CD010550. doi: 10.1002/14651858.CD010550.pub2.
Bosch E, Ezcurra D. Individualised controlled ovarian stimulation (iCOS): maximising success rates for assisted reproductive technology patients. Reprod Biol Endocrinol. 2011;9:82.
van Loendersloot LL, et al. Individualized decision-making in IVF: calculating the chances of pregnancy. Hum Reprod. 2013;28(11):2972–80.
Wong JM, Forrest KA, Snabes SZ, et al. Efficacy of nafarelin in assisted reproductive technology: a meta-analysis. Hum Reprod Update. 2001;7(1):92–101.
Pacchiarotti A, et al. Ovarian stimulation protocol in IVF: an up-to-date review of the literature. Curr Pharm Biotechnol. 2016;17(4):303–15.
Stimpfel M, et al. Comparison of GnRH agonist, GnRH antagonist, and GnRH antagonist mild protocol of controlled ovarian hyperstimulation in good prognosis patients. Int J Endocrinol. 2015;2015:385049.
Al-Inany HG, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750.
Olivennes F, et al. Multiple Dose International Study Group.; Cetrotide Single Dose International Study Group. Safety and efficacy of a 3 mg dose of the GnRH antagonist cetrorelix in preventing premature LH surges: report of two large multicentre, multinational, phase IIIb clinical experiences. Reprod Biomed Online. 2003;6(4):432–8.
Wilcox J, et al. Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. Fertil Steril. 2005;84(1):108–17.
Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online. 2007;14(5):640–9.
Krishna D, Dhoble S, Praneesh G, Rathore S, Upadhaya A, Rao K. Gonadotropin-releasing hormone agonist trigger is a better alternative than human chorionic gonadotropin in PCOS undergoing IVF cycles for an OHSS Free Clinic: A Randomized control trial. J Hum Reprod Sci. 2016;9(3):164–72.
Popovic-Todorovic B, Loft A, Lindhard A, Bangsbøll S, Andersson AM, Andersen AN. A prospective study of predictive factors of ovarian response in ‘standard’ IVF/ICSI patients treated with recombinant FSH. A suggestion for a recombinant FSH dosage normogram. Hum Reprod. 2003;18(4):781–7.
Pouly JL, French CONSORT Study Group, et al. Usability and utility of the CONSORT calculator for FSH starting doses: a prospective observational study. Reprod Biomed Online. 2015;31(3):347–55.
Garcia-Velasco JA, et al. Cycle scheduling with oral contraceptive pills in the GnRH antagonist protocol vs the long protocol: a randomized, controlled trial. Fertil Steril. 2011;96(3):590–3. doi:10.1016/j.fertnstert.2011.06.022.
Banker M, Garcia-Velasco JA. Revisiting ovarian hyper stimulation syndrome: Towards OHSS free clinic. J Hum Reprod Sci. 2015;8(1):13–7. doi:10.4103/0974-1208.153120.Review.
Kwan I, Bhattacharya S, Kang A, Woolner A. Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). Cochrane Database Syst Rev. 2014;24(8):CD005289. doi: 10.1002/14651858.CD005289.pub3.
Cakmak H, Rosen MP. Random-start ovarian stimulation in patients with cancer. Curr Opin Obstet Gynecol. 2015;27(3):215–21.
Requena A, et al. Evaluation of the degree of satisfaction in oocyte donors using sustained-release FSH corifollitropin α. Reprod Biomed Online. 2013;26(3):253–9.
Fatemi HM, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril. 2014;101(4):1008–11.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Iglesias, C., García-Velasco, J.A. (2018). Ovarian Stimulation Prior to Elective Oocyte Cryopreservation. In: Stoop, D. (eds) Preventing Age Related Fertility Loss. Springer, Cham. https://doi.org/10.1007/978-3-319-14857-1_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-14857-1_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-14856-4
Online ISBN: 978-3-319-14857-1
eBook Packages: MedicineMedicine (R0)